For approximately one-third of estrogen receptor (ER)-positive breast cance
r patients, extracted tumor ER is unable to bind to its cognate DNA estroge
n response element (ERE), an effect that is partly reversible by the thiol-
reducing agent dithiothreitol (DTT). Full-length (67 kDa) ER or its 11 kDa
recombinant DNA-binding domain (ER-DBD) is also susceptible to loss of stru
cture and function by the action of oxidants such as diamide and hydrogen p
eroxide; however, prior DNA binding by ER or ER-DBD protects against this o
xidant induced loss of function. The ER-DBD contains two (Cys)(4)-liganded
zinc finger motifs that cooperate to stabilize a rigid DNA-binding recognit
ion helix and a flexible helix-supported dimerization loop, respectively. C
omparisons between synthetic peptide analogues of each zinc finger and reco
mbinant ER-DBD in the presence of zinc by electrophoretic mobility shift as
say, circular dichroism, and mass spectrometry confirm that cooperativity b
etween these zinc fingers is required for both ER-DBD structure (alpha-heli
city) and function (dimeric DNA binding). Rapid proteolytic digestion of mo
nomeric, non-DNA-bound ER-DBD followed by HPLC-MS analysis of the resulting
peptides demonstrates that zinc inhibits thiol oxidation of the DNA-bindin
g finger, but not the finger supporting the flexible dimerization loop, whi
ch remains sensitive to internal disulfide formation. These findings indica
te that the loss of ER DNA-binding function in extracts from some primary b
reast tumors and in ER or ER-DBD exposed to thiol-reacting oxidants results
from this asymmetric zinc finger susceptibility to disulfide formation tha
t prevents dimerization. Although ER-DBD contains several strategically loc
ated methionine residues, they are less susceptible to oxidation than the t
hiol groups and, thus, afford no protection against cysteine oxidation and
consequent loss of ER DNA-binding function.